Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Drug Utilization Trends of IonChannel–Targeted Medications in Sweden: A Cross–Sectional Study
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
2025 (English)Independent thesis Advanced level (degree of Master (Two Years)), 20 credits / 30 HE creditsStudent thesis
Abstract [en]

Background: Ion channels are protein structures vital for maintaining physiological andpathological processes and a disruption of their function may result in multiple diseases. Ionchannel-targeted medications (ICTMs) act by modulating different types of ion channels. A gapin knowledge exists regarding the presence of utilization trends of ICTMs in Sweden. Aim: To provide an overview regarding the consumption of ICTMs used against type-2 diabetes mellitus(T2DM), cardiovascular diseases (CVDs), epilepsy and cystic fibrosis (CF) in Sweden. To alsoinvestigate the presence of differences in the utilization of ICTMs between hospital usage andoutpatient prescription. Furthermore, to identify gender and age impacts on ICTMconsumption. Method: A cross–sectional study based on register data between 2006 and 2024.Data were collected from the Swedish National Prescribed Drug Register and the sales data ofhospitals from the Swedish e–Health Agency. Measurements used were in patients/1000inhabitants (PAT/TIN) and defined daily dose/1000 inhabitants per day (DDD/TID). Descriptivestatistical methods were used to analyse the data. Results: The utilization trends of ICTMstargeting T2DM show a general decrease in usage, where the usage of glibenclamide decreasesfrom 6.64 PAT/TIN to 0 PAT/TIN in 2022. While the usage of ICTMs against CVD and epilepsyvary according to their substance class. Usage of ICTMs against CF has generally increased, asthe ICTM containing the combination of elexacaftor/tezacaftor/ivacaftor increases from 0PAT/TIN to 0.06 in 2024. Some trends may be explained by changes in therapeutic guidelines andobserved side effects. There were differences present in the use of ICTMs between hospital usageand outpatient prescriptions, where dispensed prescriptions dominated. Gender–based differenceswere found in the consumption of some ICTMs targeting T2DM, CVDs and epilepsy, but not forCF. Age also had a substantial impact on the utilization trends of all ICTMs. Conclusion: Anoverview was provided on the usage of ICTMs, but further research is required, using other typesof studies, to draw conclusions on the causations of the observed trends.

Place, publisher, year, edition, pages
2025.
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-573181OAI: oai:DiVA.org:uu-573181DiVA, id: diva2:2020909
Supervisors
Examiners
Available from: 2025-12-12 Created: 2025-12-11 Last updated: 2025-12-12Bibliographically approved

Open Access in DiVA

No full text in DiVA

By organisation
Department of Pharmacy
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 18 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf